BACKGROUND AND AIM: In China, inappropriate therapies with nucleos(t)ide analogues (NA) have induced @entity97 resistance, combination therapy with @entity8742 and @entity4334 (ComTNsNt) failure or multi-drug resistant mutations. However, the efficacy of combination therapy with @entity17705 plus @entity15833 for ComTNsNt failure is limited. In the current study, the regimens of @entity686 therapy, switching from NAs to @entity686 and subsequent re-treatment with @entity686 were applied to treat ComTNsNt failure. We further evaluated the efficacy of this therapy. METHODS: Eleven @entity1 with ComTNsNt failure were enrolled in this study. Nine subjects (9/11) received @entity686 switching therapy. Combination therapy with @entity686 and ComTNsNt was administered in the first 4   weeks. Then, ComTNsNt was discontinued at the end of week 4, and @entity686 monotherapy was continued for 6   months. Two (2/11) @entity1 discontinued ComTNsNt without receiving @entity686 treatment. All 11 @entity1 received the 1(st) re-treatment of @entity686 when they experienced @entity99 relapses after the withdrawal of @entity686 or ComTNsNt. @entity13657 ) @entity1 received a 2(nd) re-treatment of @entity686 . Follow-up was conducted after @entity686 therapy in all 11 @entity1 . RESULTS: Two @entity1 (2/9) receiving @entity686 switching therapy experienced ALT flare. In contrast, the two @entity1 without @entity686 switching therapy experienced ALT flare. Multiple re-treatments with @entity686 resulted in a sustained response. CONCLUSION: @entity686 switching therapy and @entity686 re-treatment might be applied for treatment of ComTNsNt failure. @entity686 switching therapy resulted in safe ComTNsNt cessation, and @entity686 re-treatment induced a sustained response of @entity686 in all @entity1 . This @entity686 treatment is an optional treatment for ComTNsNt failure.

Efficacy of interferon for chronic hepatitis B in @entity1 with XXXX and @entity4334 combination therapy failure.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity97 :: ('10407', 'Species') :: ['HBV'] @entity686 :: ('3438', 'Gene') :: ['IFN-a'] @entity13657 :: ('4990', 'Gene') :: ['Six (6/11'] @entity8742 :: ('D009705', 'Chemical') :: ['nucleoside'] @entity17705 :: ('MESH:C413685', 'Chemical') :: ['entecavir'] @entity15833 :: ('MESH:C096918', 'Chemical') :: ['tenofovir'] @entity4334 :: ('D009711', 'Chemical') :: ['nucleotide'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatitis']
@entity8742 :: (D009705,Chemical) :: ['nucleoside']
